Conclusions
The near doubling of the pathologic complete response rate seen for weekly scheduling in this trial motivates further examination of this schedule in early-stage breast cancer.
Rights and permissions
About this article
Cite this article
Seidman, A.D., Norton, L. Neoadjuvant weekly paclitaxel followed by FAC. Curr Oncol Rep 7, 9 (2005). https://doi.org/10.1007/s11912-005-0018-9
Issue Date:
DOI: https://doi.org/10.1007/s11912-005-0018-9